Sabine D. Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, shared a post on X by UroToday.com adding:
“Interesting exchange in recurrent LG IR NMIBC:
- Personalized treatment and Risk Stratification is the key
- Exploration of new treatment options
- High quality unitial TURBT is important
Quoting UroToday.com’s post below:
“To TURBT or Not to TURBT? Evaluating treatment options for recurrent low-grade, intermediate-risk bladder tumors.”
Source: Sabine D. Brookman-May/X and UroToday.com/X